Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Dec. 2024,
Accelerate Diagnostics paidMXN0.0 Mil more to buy back shares than it received from issuing new shares.
It spentMXN0.8 Mil paying down its debt.
It paidMXN0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedMXN0.0 Mil from paying cash dividends to shareholders.
It spentMXN11.4 Mil on other financial activities.
In all, Accelerate DiagnosticsspentMXN12.2 Mil on financial activities for the
three
months ended in Dec. 2024.
Accelerate Diagnostics (MEX:AXDX) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Accelerate Diagnostics's issuance of stock for the
three
months ended in Dec. 2024 was MXN0.0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Accelerate Diagnostics's repurchase of stock for the
three
months ended in Dec. 2024 was MXN0.0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Accelerate Diagnostics's net issuance of debt for the
three
months ended in Dec. 2024 was MXN-0.8 Mil.
Accelerate Diagnostics spentMXN0.8 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Accelerate Diagnostics's net issuance of preferred for the
three
months ended in Dec. 2024 was MXN0.0 Mil.
Accelerate Diagnostics paidMXN0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Accelerate Diagnostics's cash flow for dividends for the
three
months ended in Dec. 2024 was MXN0.0 Mil.
Accelerate Diagnostics receivedMXN0.0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Accelerate Diagnostics's other financing for the
three
months ended in Dec. 2024 was MXN-11.4 Mil.
Accelerate Diagnostics spentMXN11.4 Mil on other financial activities.
Accelerate Diagnostics Cash Flow from Financing Related Terms
Accelerate Diagnostics Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Accelerate Diagnostics's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accelerate Diagnostics Cash Flow from Financing Chart
Accelerate Diagnostics Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Accelerate Diagnostics's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN494.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of MXN494.7 Mil mean?
Accelerate Diagnostics (MEX:AXDX) has a Cash Flow from Financing of MXN494.7 Mil as of Dec. 2024. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Accelerate Diagnostics and its competitors.
Is Accelerate Diagnostics' Cash Flow from Financing too high?
Accelerate Diagnostics' current Cash Flow from Financing is MXN494.7 Mil. Overall, Accelerate Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Accelerate Diagnostics' Cash Flow from Financing compare to MSIU and BIOLQ?
Accelerate Diagnostics' Cash Flow from Financing of MXN494.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Accelerate Diagnostics and its competitors. Accelerate Diagnostics's current Cash Flow from Financing is MXN494.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accelerate Diagnostics stock overvalued right now?
Accelerate Diagnostics (MEX:AXDX) has a current Cash Flow from Financing of MXN494.7 Mil. The current Cash Flow from Financing is MXN494.7 Mil. Accelerate Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Accelerate Diagnostics (MEX:AXDX), the current Cash Flow from Financing is MXN494.7 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
12GF Score
Get the complete analysis for MEX:AXDX
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AXDX has been successfully added to your 
